| Combination of | |
|---|---|
| Pseudoephedrine | Sympathomimetic |
| Loratadine | H1 antagonist |
| Clinical data | |
| Trade names | Claritin-D, others |
| AHFS/Drugs.com | claritin-d |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Pseudoephedrine/loratadine, sold under the brand nameClaritin-D among others, is an orally administeredcombination medication used for the treatment ofallergic rhinitis (hay fever) and thecommon cold.[1]Pseudoephedrine, one of the naturally occurring alkaloids ofephedra, is asympathomimetic used as adecongestant.[medical citation needed] It produces a decongestant effect that is facilitated by thevasoconstriction in the mucosal capillaries of the upper respiratory areas.[medical citation needed]Loratadine is a long-actingantihistamine (H1 histamine antagonist) that is lesssedating than older substances of its type.[medical citation needed]
In 2023, it was the 300th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.[2][3]
Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion,sneezing,rhinorrhea,pruritus, andlacrimation.[1][4]
 | This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(July 2024) (Learn how and when to remove this message) |
A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.
Interactions, adverse effects and contraindications are described in more detail in the articles aboutpseudoephedrine andloratadine.
| This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(July 2024) (Learn how and when to remove this message) |
When sympathomimetics are given to patients receivingmonoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, includinghypertensive crises may occur.
| This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(July 2024) (Learn how and when to remove this message) |
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception ofinsomnia and dry mouth, both of which were commonly reported.
| This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(July 2024) (Learn how and when to remove this message) |
Pseudoephedrine/loratadine is contraindicated in people receivingMAO inhibitor therapy or within 14 days of discontinuing such treatment and in people with narrow angleglaucoma, urinary retention, severehypertension, severecoronary artery disease andhyperthyroidism.
It is sold under various brand names including Claritin-D, Clarinase, Clarinase Repetabs, Lorinase, Rhinos SR, and Allerclear-D.
